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Abstract The most common diseases of the joints and
its tissues are osteoarthritis and rheumatoid arthritis,
with osteoarthritis being anticipated to be the fourth
leading cause of disability by the year 2020. To date,
no truly causal therapies are available, and this has
promoted tissue engineering attempts mainly involving
mesenchymal stem cells. The goal of all tissue repairs
would be to restore a fully functional tissue, here a
hyaline articular cartilage. The hyaline cartilage is the
most affected in osteoarthritis, where altered cell–matrix
interactions gradually destroy tissue integrity. In rheu-
matoid arthritis, the inflammatory aspect is more impor-
tant, and the cartilage tissue is destroyed by the inva-
sion of tumor-like pannus tissue arising from the in-
flamed synovia. Furthermore, the fibrocartilage of the
meniscus is clearly involved in the initiation of osteo-
arthritis, especially after trauma. Recent investigations
have highlighted the role of migratory progenitor cells
found in diseased tissues in situ. In osteoarthritis and
rheumatoid arthritis, these chondrogenic progenitor cells
are involved in regeneration efforts that are largely
unsuccessful in diseased cartilage tissue. However, these pro-
genitor cells are interesting targets for a cell-based regenera-
tive therapy for joint diseases.
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Introduction
Mesenchymal stem cells (MSCs) reside in differentiated tis-
sues and are often responsible for self-repair after trauma or
disease. Their potential for a regenerative therapy of diseased
cartilage has been recently summarized [1, 2]. MSCs are
involved in the regeneration of mesenchymal tissues, for
example, bone, cartilage, muscle, ligament, tendon, adipose,
and stroma [3, 4, 5••, 6, 7], Pittenger et al. (1999) were the first
to isolate adult MSCs from bone marrow and demonstrated
their multilineage potential [8]. Subsequently, researchers iso-
lated MSCs from various other adult tissues, such as blood,
adipose, skin, mandible trabecular bone, muscle, synovial
membrane and synovial fluid [9]. The diversity of the
chondrogenic potential of MSCs isolated from these different
tissues is still being investigated. An increased number of
MSCs are observed in the synovial fluid of osteoarthritis
(OA) patients [8]. Wakitani et al. performed the first trans-
plantation of bone marrow-derived mesenchymal stem cells
for cartilage repair in human OA, and a sort of cartilage-like
tissue was observed after 42 weeks [10]. However, no single
method is yet fully efficient for cartilage tissue regeneration by
generating a functional tissue that lasts over time. In OA of
late disease stages, the cartilage defects are often rather
large, this, together with the cartilage-degrading milieu,
makes tissue regeneration attempts especially difficult. MSCs
have also been investigated in the context of rheumatoid
arthritis (RA), here especially their immune modulatory prop-
erties are important [11].
OA is a degenerative joint disease with progressive loss of
the articular cartilage and eburnation of the subchondral bone
[12, 13••]. Furthermore, the disease is characterized as an
whole organ disease [12, 13••] also involving the synovia
[14, 15••] and the meniscus [16]. Recently, it has been dem-
onstrated that the inflammation mediators found in OA are
produced by the synovium, and not the cartilage tissue itself
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[17]. According to Reginster [18], nearly 1.75 million patients
in England and Wales alone suffer from symptomatic OA,
suggesting that it is the most commonmusculoskeletal disease
worldwide. There is a strong association between increasing
age and OA prevalence. Up to 20 % of the population over
60 years old shows signs of the disease [19]. OA often remains
asymptomatic until late in the disease progression, and reliable
early markers for diagnosis are still lacking. Therefore, total
knee replacement is the gold standard treatment [19].
Meniscal lesions also lead to OA [16], and a high interde-
pendency of OA with meniscal lesions has been described
[20]. In total, 1.5 million knee arthroscopies are performed
annually, and meniscal injuries account for more than 50 % of
those operations [21, 22]. The prevalence of meniscal tears
increases with age [23••] and may be as high as 56 % in men
aged 70–90 years old [21]. Allografts or bio-engineered
meniscal substitutes [24] can be applied after the removal of
the meniscus; however, radiological and MRI scans show no
protective effect against the development of OA [25]. The
reasons for this lack of protection are still unknown. The
failure to successfully remodel the allograft into a living tissue
is one likely factor [26]. Therefore, almost all patients even-
tually require joint replacement [22].
Rheumatoid arthritis (RA) is the most common chronic
inflammatory joint disease. It leads to progressive cartilage
and bone destruction, but the time course and cellular mech-
anisms are somewhat different from those in OA. Full or
partial work incapacitation will burden 35 % of RA patients
within 10 years of RA onset [27]. Novel cell biological
therapies have substantially improved patient outcomes [28].
Fig. 1 a Late stage OA from a
patient after surgery for total knee
replacement. Note the multiple
tidemarks (arrows) and the cluster
formation (asterisk). b
Fibrocartilagenous repair tissue
with scar-like appearance. c
Mesenchymal tissue is entering
the cartilage tissue (arrow) from
underneath the tidemark allowing
cell migration from the bone
marrow into the diseased cartilage
tissue. Bar (a–c) 150 μm
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However, the serious side effects of these biological therapies
and the non-response rate of up to 40 or 50 % warrant the
development of novel treatment options. Chronic synovial
inflammation with tumor-like pannus overgrowth of the car-
tilage is responsible for the joint cartilage destruction.
Fibroblast-like synoviocytes and synovial macrophages have
been extensively investigated for their involvement in the
inflammatory process through the production of proinflam-
matory cytokines, such as IL-1ß, IL-6, TNF-α, and matrix
metalloproteinases [29]. Bone destruction in RA occurs main-
ly via the RANKL-dependent induction of osteoclasts [30].
Furthermore, CD4+ T-cells accumulate within the RA
synovium [31, 32], and subpopulations mediate chronic sy-
novial inflammation [33].
Once damaged or injured, the articular cartilage and the
inner meniscus have limited intrinsic self-repair abilities
(Fig. 1) because of their avascular nature. All regenerative
therapeutic interventions need to address how to generate a
repair tissue that has the same mechano-biological properties
as the native hyaline articular cartilage. This neo-tissue also
needs to integrate well with the articular cartilage in place
[34]. To date, there is no method to derive a chondrogenic
lineage from stem cells that will form functional hyaline
cartilage tissue in vivo [35, 36]. Therefore, our approach is
to utilize the repair cells present in the late stages of disease. In
this review, we focus on the progenitor cells found in situ in
osteoarthritic cartilage from OA patients, in the hyaline carti-
lage of RA patients, and in the inner, avascular part of the
meniscus of OA patients. One line of research for cartilage
repair is to optimize the performance of MSCs applied from
outside, or to utilize the disease modulatory properties of these
MSC. We introduce another concept, of investigating the role
of chondrogenic progenitor cells found inside the diseased
joint. To learn to understand their biology will render it
possible to manipulate them in the future to utilize the poten-
tial of these repair cells already present in the diseased joint or
to recruit progenitor cells to the diseased joint by enhancing
their migration capacity.
Migration of Stem Cells
The migration of epithelial and mesenchymal cells is a well-
known mechanism that occurs during various biological pro-
cesses [37]. Epithelial cell migration is essential for wound
healing of the skin [38••], and mesenchymal cell migration is
needed for many repair processes throughout life [39].
Hematopoiesis would not be possible without cell migration
[40], and bone regeneration involves circulating osteogenic
cells [41]. Furthermore, the basic biological processes of the
stem cell niche, especially the generation of the transient,
amplifying pool of progenitor cells, are dependent on migra-
tion processes [42]. Therefore, migratory capacity is a char-
acteristic needed for proper differentiation of mesenchymal
stem cells, although it is not listed in the current definition of
mesenchymal stem cell characteristics, which include multi-
differentiation potential, stem cell marker positivity, and clo-
nicity. In this context, it is interesting to see that the progenitor
Fig. 2 The migratory potential of chondrogenic progenitor cells from
OA tissue in an ex vivo experiment. GFP-labeled cells were placed on
OA tissue, and the cells migrated deep into the tissue. Taken from
Koelling et al. [32] with permission of the publisher
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cell populations from patient tissues from the late stages
of OA exhibit a strong migratory potential at least in vitro
(Fig. 2).
Chondrogenic Progenitor Cells from OA Patients (CPCs)
During the more advanced stages of OA, the fibrocartilaginous
cartilage contains collagens, such as type I and type III [43–45],
while we find the amount of collagen type II decreases as seen
by quantitative immunohistochemistry [44]. In contrast, micro-
array investigations demonstrate an overall increased anabo-
lism and an up-regulation of mRNAs also of cartilage-specific
collagens [46, 47]. In any case, the altered matrix composition
seems to be one reason for the long-term failure of the repair
tissue to initiate a restitutio ad integrim. We identified
chondrogenic progenitor cells (CPCs) as a subpopulation of
cells found in the repair tissue of late stages of OA [48]. These
cells not only exhibit a high migratory potential in vitro as well
as ex vivo (Fig. 3) but they are positive for stem cell markers
(for example, CD29, 73, 90, 105) and can be differentiated into
adipocytes, cells of the osteoblastic lineage, and chondrocytes.
The CPCs, also referred to as osteo-chondro progenitor cells
[49], are under the control of the transcription factors Runx2
and Sox9 [48, 50]. RNA interference was applied to down-
regulate the osteogenic transcription factor Runx2, with
concomitant up-regulation of Sox9, the chondrogenic transcrip-
tion factor, and consequently enhanced COL2A1 mRNA in an
ex vivo experiment. Currently, we elaborated a knock-down/
pull-down experiment combined with a proteomic analysis to
identify adaptor molecules involved in the up-regulation of
Sox9. This method will lead to a drug development strategy
targeting small, modifying molecules that can enhance chon-
drogenesis during the late stages of OA. This multifaceted
disease involves many diverse tissues, such as the synovium,
fibrous capsule, hyaline cartilage, subchondral bone, and the
meniscus, and has many pathogenic factors, such as extracel-
lular matrix-degrading enzymes and its inflammatory cyto-
kines. Therefore, this disease will not be substantially influ-
enced by only one biological therapy. We envision a combina-
torial approach with anti-inflammatory, anti-matrix-degrading
measures, and the utilization of intrinsic progenitor cells.
Chondrogenic Progenitor Cells from RA Patients (RA-CPCs)
Recently, we also characterized CPCs from diseased cartilage
tissue from RA patients. These RA-CPCs are negatively in-
fluenced by interleukins present in the inflammatory environ-
ment of the RA joint and are therefore less chondrogenic
(Fig. 4). RA-CPCs produce high levels of matrix metallopro-
teinases and proinflammatory cytokines under the influence of
Fig. 3 a Chondrogenic progenitor cells migrating from an OA cartilage
sample to the surface of a culture dish. b A migrating cell at the ultra-
structural level near the tidemark of OA tissue (usedwith permission from
Koelling [32]). c The migratory chondrogenic progenitor cells are posi-
tive for Runx2 as shown by immunofluorescence (green staining), and d
they are also positive for Sox9 as shown by western blotting
Fig. 4 a Chondrogenic progenitor cells migrating from an RA cartilage sample. b The cells are positive for the IL17 receptor as shown here by
immunocytochemistry and c by western blotting. Bar (a, b) 150 μm
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IL-17. Anti-inflammatory agents enable the cells to regain
their chondrogenic capacity. Additionally, these RA-CPCs
have high migration potential and can repopulate diseased
cartilage tissue ex vivo. In vitro, IL-17A/F affects RA-CPC
migration. In comparison, growth factors (EGF, IGF, PDGF)
and the proinflammatory cytokine TNF-α, RA-CPCs can
migrate equally well toward a gradient of EGF, TNF-α, or
IL-17A/F (manuscript in preparation). This result underlines
the important influence of inflammatory mediators on progen-
itor cells, especially on cell migration processes.
Meniscus Progenitor Cells (MPCs)
Over the last years, we have also investigated diseased human
menisci from patients in the late stages of OA. A new classifi-
cation system together with the results from transcriptomic and
proteomic analyses enabled us to discriminate healthy and
diseased humanmeniscus specimens. Interestingly, the samples
receiving a high disease score also exhibited down-regulation
of TGFß and Smad2. One consequence of the down-regulation
of TGFß and Smad2 is the up-regulation of Runx2. The TGFß/
BMP pathway, with its dual osteogenic and chondrogenic
actions, is a good candidate for further investigation. We also
identified progenitor cells in the inner, avascular part of the
diseased human meniscus, similar to the CPCs and RA-CPCs
found in the cartilage:. Thesemeniscus progenitor cells (MPCs)
normally produce collagen type I, and they are fibro-
cartilagenous in nature [51]. MPCs also exhibit a high migra-
tory potential (Fig. 5). The initial results indicate that MPCs are
also governed by a balance between the transcription factors
Runx2 and Sox9. The knock-down of Runx2 in MPCs en-
hances p-Smad2 and drives them towards the chondrogenic
Fig. 5 a The diseased meniscus is lacking the superficial zone with
flattened cells and is only comprised of the round fibro-chondrocytes in
the inner zone. bThemeniscus progenitor cells (MPCs) are governed by the
TGFβ pathway mediator Smad2, as shown here by immunohistochemistry.
c Additionally, these MPCs migrate into diseased meniscus tissue. GFP-
positive cells are found in the outer third of the OA meniscus. Bar (a–c)
150 μm
Fig. 6 Schematic of our concept
of chondrogenic progenitor cells
in situ and their role in cartilage
repair. Mesenchymal stem cells
(MSCs) enter the cartilage tissue
most likely from the bone marrow
to become an osteo-chondro
progenitor cell population. These
osteo-chondro progenitor cells
differentiate into chondrogenic
progenitor cells (CPCs). In late
stages of OA, they generate
fibrocartilage rich in collagen
type I in a scar-like repair tissue.
Our aim is to drive these CPCs in
situ into the chondrogenic lineage
by the manipulation of the
transcription factors Runx2
and Sox9
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differentiation. In contrast, BMP2 stimulation ofMPCs reduces
Smad2 levels and enables the MPCs to move towards the
osteogenic lineage [51].
Chondrogenic Progenitor Cells and Their Role in Cartilage
Repair
We have isolated migratory progenitor cell populations from
late-stage human OA cartilage, RA cartilage, and osteoarthrit-
ic meniscus. These cells are positive for the well-known stem
cell markers CD105, CD106, CD73, CD29 and Stro-1; how-
ever, their individual stem cell marker profiles vary. Whether
the CPCs are unique from the cells exhibiting a similar stem
cell marker profile in vitro, which have been identified in
cartilage tissue after enzymatic digestion [52–55], has not
been investigated, The relationship of CPCs to the cells found
in the superficial zone of healthy cartilage tissue in vivo, also
exhibiting a stem cell marker, is also not clear [56]. However,
the CPCs differ in that they exhibit a high migratory potential
[57], and all CPCs identified so far seem to be regulated by a
balance between the transcription factors Runx2 and Sox9.
The knock-down of Runx2 consistently enhances the
chondrogenic potential of CPCs, RA-CPCs, and MPCs
via by up-regulation of Sox9 and collagen II expression
[48, 50, 51].
Our studies on progenitor cells have revealed exciting data
with a future potential for the clinical application of CPCs for
cartilage repair [48, 50, 51]. Our aim is to manipulate these
progenitor cells in situ with the help of small modifying
molecules to enhance their chondrogenic potential. We sug-
gest that the resident cells in the diseased cartilage tissue are
the ideal candidates for in situ manipulation for regenerative
therapy applications (Fig. 6). These cells are already active in
the diseased tissue and may be more efficient and safer than
exogenous cells. To date, we have elucidated the
chondrogenic pathways of progenitor cells to find adaptor
molecules of two of their master regulators, Sox9 and
Runx2, to promote Sox9 expression. However, even if we
succeed in identifying small molecules that enhance Sox9
expression (and thereby the synthesis of collagen type II),
further research is required. Obviously, the strong influences
of age, gender, and body weight on the regenerative capacity
of the progenitor cells should be considered, as has already
been described for MSCs [58]. Further, the guidance of these
cells to the diseased area has to take into account the surround-
ing tissue, which is filled with negative mediators that pro-
mote degradation and inflammation. Other groups have also
investigated the migratory potential of CPCs, and have found
that interleukin-1 beta and tumor necrosis factor alpha
inhibit their migration [59]. In line with this, CPCs also
exhibit a tendency to over-express chemokines that pro-
mote chemotaxis possibly involving their general migratory
potential [60].
Conclusion
In recent years, progress has been made in understanding the
pathogenesis of OA and human articular cartilage degrading
processes. The involvement of migratory progenitor cells has
become more important. However, many details of the bio-
logical mechanisms governing these cells remain to be eluci-
dated. How do we tip the balance of the transcription factors
Runx2 and Sox9 to favor the latter to enhance chondrogenesis
in the progenitor cells? Additionally, how do we use their
migratory capacity to guide them toward the lesion? Taken
together, we suggest that the manipulation of migratory pro-
genitor cells in situ might be a feasible way to facilitate the
regeneration efforts in vivo to enhance the restitution ad
integrim in osteoarthritic cartilage tissue.
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